Vivoryon Therapeutics N.V.
VVY.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.58 | -0.08 | 1.25 |
| FCF Yield | -37.01% | -10.75% | -9.60% | -2.97% |
| EV / EBITDA | -2.09 | -6.58 | -7.13 | -30.38 |
| Quality | ||||
| ROIC | -209.51% | -103.17% | -102.21% | -67.46% |
| Gross Margin | 0.00% | 85.50% | 0.00% | 83.89% |
| Cash Conversion Ratio | 0.93 | 0.76 | 0.77 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 13.05% | -1.14% | -93.24% | 22.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 0.65 | 0.94 | 1.20 |
| Interest Coverage | -243.73 | -514.95 | -1,213.83 | -533.58 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,520.24 | 1,962.11 | -5,765.19 | -803.83 |